Abstract: The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF? and OSM that can be formulated for topical administration for cosmetic or dermatologic use.
Type:
Grant
Filed:
September 29, 2014
Date of Patent:
September 25, 2018
Assignees:
Universite D'Angers, Universite de Poitiers, Bioalternatives SAS
Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNF?, IL-31, IFN-?, and/or the OSMR? subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.
Type:
Application
Filed:
October 27, 2011
Publication date:
June 7, 2012
Applicants:
UNIVERSITE D'ANGERS, BIOALTERNATIVES SAS, UNIVERSITE DE POITIERS
Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNF? and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.
Type:
Grant
Filed:
December 15, 2005
Date of Patent:
March 8, 2011
Assignees:
Universite d'Angers, Universite de Poitiers, Bioalternatives SAS
Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNF?, IL-31, IFN-?, and/or the OSMR? subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.
Type:
Application
Filed:
December 15, 2005
Publication date:
December 3, 2009
Applicants:
UNIVERSITE D'ANGERS, UNIVERSITE DE POITIERS, BIOALTERNATIVES SAS